All
How to Avoid Falling through the Cracks: Cancer Assistance Tips
November 14th 2018Cancer is costly. What if I did not have health insurance or a steady paycheck? Would I have fallen through the cracks and died of metastatic breast cancer before anybody told me I was sick? An exercise in role-playing taught me that there is help available.
FDA Grants Priority Review to Tecentriq Combination for Triple Negative Breast Cancer
November 13th 2018The Food and Drug Administration granted a priority review to Tecentriq (atezolizumab) plus Abraxane (nab-paclitaxel) for the frontline treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in patients whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing, according to Roche, the drug’s manufacturer.
FDA Grants Lynparza Priority Review for Frontline Maintenance in Ovarian Cancer
November 12th 2018The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for Lynparza (olaparib) tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.
Moving Mountains to Find a Cure
November 9th 2018"In the midst of all of the difficulty of trying to deal with something this terrible, having that hope in your back pocket is invaluable to my life and to my family." - Brian Smith, on living with multiple myeloma and participating in Moving Mountains for Multiple Myeloma's recent Iceland trek.
Exercise Reduces Fatigue, Physical Well-Being Among Patients With Advanced Lung Cancer
November 8th 2018Many patients with lung cancer may experience side effects, such as fatigue and shortness of breath, that can prevent them from exercising. However, for the first time, new research findings showed benefits from exercise in those with advanced disease.
FDA Grants Fast Track Designation to Selinexor to Treat Diffuse Large B-cell Lymphoma
November 7th 2018The Food and Drug Administration (FDA) granted fast track designation to selinexor for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), according to Karyopharm Therapeutics, the drug’s manufacturer.